Your browser doesn't support javascript.
loading
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer.
Zabala-Letona, Amaia; Arruabarrena-Aristorena, Amaia; Martín-Martín, Natalia; Fernandez-Ruiz, Sonia; Sutherland, James D; Clasquin, Michelle; Tomas-Cortazar, Julen; Jimenez, Jose; Torres, Ines; Quang, Phong; Ximenez-Embun, Pilar; Bago, Ruzica; Ugalde-Olano, Aitziber; Loizaga-Iriarte, Ana; Lacasa-Viscasillas, Isabel; Unda, Miguel; Torrano, Verónica; Cabrera, Diana; van Liempd, Sebastiaan M; Cendon, Ylenia; Castro, Elena; Murray, Stuart; Revandkar, Ajinkya; Alimonti, Andrea; Zhang, Yinan; Barnett, Amelia; Lein, Gina; Pirman, David; Cortazar, Ana R; Arreal, Leire; Prudkin, Ludmila; Astobiza, Ianire; Valcarcel-Jimenez, Lorea; Zuñiga-García, Patricia; Fernandez-Dominguez, Itziar; Piva, Marco; Caro-Maldonado, Alfredo; Sánchez-Mosquera, Pilar; Castillo-Martín, Mireia; Serra, Violeta; Beraza, Naiara; Gentilella, Antonio; Thomas, George; Azkargorta, Mikel; Elortza, Felix; Farràs, Rosa; Olmos, David; Efeyan, Alejo; Anguita, Juan; Muñoz, Javier.
Afiliación
  • Zabala-Letona A; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Arruabarrena-Aristorena A; CIBERONC.
  • Martín-Martín N; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Fernandez-Ruiz S; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Sutherland JD; CIBERONC.
  • Clasquin M; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Tomas-Cortazar J; CIBERONC.
  • Jimenez J; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Torres I; AGIOS Pharmaceuticals, Cambridge, USA.
  • Quang P; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Ximenez-Embun P; Vall d'Hebron Institute of Oncology (VHIO), Universidad Autonoma de Barcelona, Barcelona, Spain.
  • Bago R; Department of Pathology, Vall d'Hebron Hospital, Universitat Autónoma de Barcelona, Barcelona, Spain.
  • Ugalde-Olano A; AGIOS Pharmaceuticals, Cambridge, USA.
  • Loizaga-Iriarte A; Spanish National Cancer Research Centre, Madrid, Spain.
  • Lacasa-Viscasillas I; MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland.
  • Unda M; Department of Pathology, Basurto University Hospital, 48013, Bilbao, Spain.
  • Torrano V; Department of Urology, Basurto University Hospital, 48013, Bilbao, Spain.
  • Cabrera D; Department of Urology, Basurto University Hospital, 48013, Bilbao, Spain.
  • van Liempd SM; Department of Urology, Basurto University Hospital, 48013, Bilbao, Spain.
  • Cendon Y; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Castro E; CIBERONC.
  • Murray S; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Revandkar A; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Alimonti A; Spanish National Cancer Research Centre, Madrid, Spain.
  • Zhang Y; Medicine School, Universidad Autónoma de Madrid.
  • Barnett A; Spanish National Cancer Research Centre, Madrid, Spain.
  • Lein G; AGIOS Pharmaceuticals, Cambridge, USA.
  • Pirman D; Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI), Bellinzona CH 6500, Switzerland.
  • Cortazar AR; Faculty of Biology and Medicine, University of Lausanne (UNIL), Lausanne CH 1011, Switzerland.
  • Arreal L; Institute of Oncology Research (IOR) and Oncology Institute of Southern Switzerland (IOSI), Bellinzona CH 6500, Switzerland.
  • Prudkin L; Faculty of Biology and Medicine, University of Lausanne (UNIL), Lausanne CH 1011, Switzerland.
  • Astobiza I; Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA.
  • Valcarcel-Jimenez L; AGIOS Pharmaceuticals, Cambridge, USA.
  • Zuñiga-García P; AGIOS Pharmaceuticals, Cambridge, USA.
  • Fernandez-Dominguez I; AGIOS Pharmaceuticals, Cambridge, USA.
  • Piva M; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Caro-Maldonado A; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Sánchez-Mosquera P; Vall d'Hebron Institute of Oncology (VHIO), Universidad Autonoma de Barcelona, Barcelona, Spain.
  • Castillo-Martín M; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Serra V; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Beraza N; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Gentilella A; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Thomas G; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Azkargorta M; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Elortza F; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
  • Farràs R; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
  • Olmos D; Department of Pathology, Fundação Champalimaud, Lisboa, Portugal.
  • Efeyan A; CIBERONC.
  • Anguita J; Vall d'Hebron Institute of Oncology (VHIO), Universidad Autonoma de Barcelona, Barcelona, Spain.
  • Muñoz J; CIC bioGUNE, Bizkaia Technology Park, 801 building, 48160, Derio, Spain.
Nature ; 547(7661): 109-113, 2017 07 06.
Article en En | MEDLINE | ID: mdl-28658205
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Poliaminas / Neoplasias de la Próstata / Adenosilmetionina Descarboxilasa / Complejos Multiproteicos / Serina-Treonina Quinasas TOR Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Nature Año: 2017 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Poliaminas / Neoplasias de la Próstata / Adenosilmetionina Descarboxilasa / Complejos Multiproteicos / Serina-Treonina Quinasas TOR Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Nature Año: 2017 Tipo del documento: Article País de afiliación: España